---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-144226"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:06:10.826836+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q1 net loss $19.3M ($23.43/sh); cash $34.2M; Nasdaq delisted

## Summary
- Net loss $19.3M ($23.43 diluted EPS); operating expenses $22.3M incl. $16.2M one-time Graybug merger costs.
- Cash, equivalents and short-term investments $34.2M as of March 31; expects runway into H2 2024.
- CARPO Phase 2b trial: IDMC reviewed first 90 pts, recommended continue; expects topline Q1 2024.
- Stock suspended from Nasdaq March 30; now trading on OTCQB, working to relist.
- Merger with Graybug closed March 20; CalciMedica equityholders own ~72%, Graybug ~28%.

## SEC filing metadata
- accession: 0001193125-23-144226
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/0001193125-23-144226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/d463877d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-144226
- JSON: https://secwatch.observer/filing/0001193125-23-144226.json
- Plain text: https://secwatch.observer/filing/0001193125-23-144226.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023., EPS $23.43 per share (basic and diluted).
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023.
  - EPS: $23.43 per share (basic and diluted)
  - Result: reported results
  source text: Financial Results for the Three Months Ended March 31, 2023: • Cash, Cash Equivalents and Marketable Securities: As of March 31, 2023, CalciMedica had $34.2 million in cash, cash equivalents and short-term investments. • Total Operating Expenses: Total operating expenses were $22.3 million, which included $16.2 million of one-time charges related to accelerated vesting and severance for employees of Graybug Vision, Inc. (Graybug) at the time of the merger with Graybug. • Net Loss: Net loss was $19.3 million, or $23.43 per share (basic and diluted), for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/0001193125-23-144226-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.